Literature DB >> 3491578

Saccade responses to dopamine in human MPTP-induced parkinsonism.

J R Hotson, E B Langston, J W Langston.   

Abstract

Depletion of dopamine content in the substantia nigra resulting from 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) toxicity produces parkinsonism. Management of 3 patients with MPTP-induced parkinsonism required drug holidays during which there was a state of dopamine depletion followed by dopamine replacement. We used this opportunity to study the effect of the selective loss of pars compacta dopaminergic cells on vertical and horizontal saccade (fast) eye movements. During the drug holidays, visually guided saccades were hypometric and had long latencies but retained a normal saccade velocity-amplitude relationship. Dopamine agonists or precursors improved the accuracy and reaction times of saccades in all directions, but not their velocity. Two of the three patients also had intermittent blepharospasm during dopamine depletion. During the episodes of blepharospasm, saccade responses became slow eye movements. MPTP causes a dopaminergic-responsive disorder of saccade initiation that is similar to idiopathic parkinsonism. The inhibition of voluntary eyelid opening during MPTP-induced blepharospasm further increases this impairment of fast eye movements and altered saccade velocity, presumably via the pars reticulata of the substantia nigra.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3491578     DOI: 10.1002/ana.410200404

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  12 in total

1.  Aging in rhesus macaques is associated with changes in novelty preference and altered saccade dynamics.

Authors:  Nathan Insel; María Luisa Ruiz-Luna; Michelle Permenter; Julie Vogt; Cynthia A Erickson; Carol A Barnes
Journal:  Behav Neurosci       Date:  2008-12       Impact factor: 1.912

2.  Multiple step pattern as a biomarker in Parkinson disease.

Authors:  Tanya Blekher; Marjorie Weaver; Jason Rupp; William C Nichols; Siu L Hui; Jacqueline Gray; Robert D Yee; Joanne Wojcieszek; Tatiana Foroud
Journal:  Parkinsonism Relat Disord       Date:  2009-02-10       Impact factor: 4.891

3.  Saccadic eye movements in essential blepharospasm.

Authors:  C J Lueck; S Tanyeri; T J Crawford; J S Elston; C Kennard
Journal:  J Neurol       Date:  1990-07       Impact factor: 4.849

4.  Subcortical input to the smooth and saccadic eye movement subregions of the frontal eye field in Cebus monkey.

Authors:  J C Lynch
Journal:  J Neurosci       Date:  1997-12-01       Impact factor: 6.167

5.  Square wave jerks in parkinsonian syndromes.

Authors:  O Rascol; U Sabatini; M Simonetta-Moreau; J L Montastruc; A Rascol; M Clanet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-07       Impact factor: 10.154

6.  Oculomotor control in Gilles de la Tourette syndrome.

Authors:  E L Bollen; R A Roos; A P Cohen; R B Minderaa; J P Reulen; B J Van de Wetering; T C Van Woerkom; O J Buruma
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-08       Impact factor: 10.154

7.  Keep focussing: striatal dopamine multiple functions resolved in a single mechanism tested in a simulated humanoid robot.

Authors:  Vincenzo G Fiore; Valerio Sperati; Francesco Mannella; Marco Mirolli; Kevin Gurney; Karl Friston; Raymond J Dolan; Gianluca Baldassarre
Journal:  Front Psychol       Date:  2014-02-21

8.  CIB1 protects against MPTP-induced neurotoxicity through inhibiting ASK1.

Authors:  Kyoung Wan Yoon; Hyun-Suk Yang; Young Mok Kim; Yeonsil Kim; Seongman Kang; Woong Sun; Ulhas P Naik; Leslie V Parise; Eui-Ju Choi
Journal:  Sci Rep       Date:  2017-09-22       Impact factor: 4.379

9.  Freezing of saccades in dopa-responsive parkinsonian syndrome.

Authors:  Techawit Likitgorn; Yan Yan; Yaping Joyce Liao
Journal:  Am J Ophthalmol Case Rep       Date:  2021-05-23

10.  Animal models for investigating benign essential blepharospasm.

Authors:  Craig Evinger
Journal:  Curr Neuropharmacol       Date:  2013-01       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.